
VERU
USDVeru Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$2.580
High
$2.650
Low
$2.580
Volume
0.18M
Company Fundamentals
Market Cap
42.5M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.18M
Exchange
NCM
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Nov 10, 2025VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges
Market Snapshot
Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns
Recent Performance: Turbulent Descent
Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:
- Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
- Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
- Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.
Technical Signals: Mixed Messages
- Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
- Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
- MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.
Fundamentals: Value Trap or Hidden Potential?
- Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
- **High-Risk
Related News
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
Veru Announces Pricing of $25 Million Public Offering
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
AI PredictionBeta
AI Recommendation
Updated at: Nov 10, 2025, 02:42 PM
58.4% Confidence
Risk & Trading
Entry Point
$2.52
Take Profit
$2.61
Stop Loss
$2.30
Key Factors
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.